![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, September 25, 2013 2:30:49 PM
seekingalpha.com/article/1712842-novavax-why-investors-are-excited-now?source=email_rt_article_readmore
Article from the Seeking Alpha link above is copied/pasted below:
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Novavax, Inc. (NVAX) describes itself as a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.
On Tuesday September 24, Novavax released a lot of information that has investors excited. Novavax has been working to bring its manufacturing platform and production process out of the Phase I and II stage into a process that it considers locked and suitable for Phase III and commercialization. My attempt with this article is to highlight for investors the important data points.
1. Game on
Novavax announced today it is preparing for the next round of clinical studies with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA), for its quadrivalent seasonal influenza vaccine and its pandemic influenza vaccine. This is an important step toward ultimate commercialization and shareholder value.
2. Well financed
Novavax also announced a public offering of $82.6 million in equity priced at $3.14 per share, near its 52-week high of $3.50 per share. It's always a good sign that large investors are willing to pony up so much money despite a stock trading near its high. The PR was vague on details as to the extent this funding will secure Novavax, but the CEO spilled the beans during the Q&A session of the presentation that followed:
We're looking to fund the program in ways that we have our flu program to the extent that we can with non-diluted financing, but it also requires investor participation. This money that we raised is designed to take us into 2016, which will get us a long way on all 3 different programs, and then, we'll see where we go from there.
Looks like investors don't have to worry about any more dilution or capital concerns or anything else financial for quite a while.
3. Possible stockpile purchase coming for Novavax H7N9 vaccine
Novavax's CEO deep in the Q&A session gave a cautionary yet eye-opening response to an analyst question:
It's somewhat difficult to predict the actions of the U.S. government or other governments. But if history prevails, BARDA and the U.S. government have, in the past, stockpiled hundreds of millions of dollars of H5N1 vaccine. They have purchased, as I think Gale pointed out, over $1 billion worth of H1N1 - Lou pointed out the H1N1, and I think that the government does stockpile. Having said that, there is not a stockpile plan in action like this minute for H7N9, but I would be surprised if there weren't at some point.
Over $1 billion in possible orders for just one vaccine for a company excited to have $80 million in financing would likely have investors causing a stampede to get into the stock. As the CEO pointed out there's no such order yet, but he would be surprised if one doesn't come.
Most of the presentation was filled with complex details about the science behind what Novavax is doing. I won't try to bore you with the details. It's the results that are exciting for the investment thesis. Financially, Novavax is very sound with plenty of cash in the bank, its programs moving forward, and it's sitting on a wild card of a possible government order to stockpile one of its vaccines. Investors can now sit back and watch the events and developments unfold, be they positive or negative, attempt to study the science and get an edge if they wish and not have to worry about the funding angle of Novavax. Often funding is a worry that eats up most of the time, research and concern of investors in development-stage biotechs. Novavax investors: worry no more.
Recent NVAX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:14:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:11:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:10:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:07:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:06:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:05:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:01:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:00:42 PM
- Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine • PR Newswire (US) • 06/14/2024 06:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 11:00:20 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/05/2024 01:35:47 AM
- Novavax to Participate in 2024 Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 01:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:24 PM
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/20/2024 06:42:06 PM
- Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting • GlobeNewswire Inc. • 05/20/2024 10:35:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/20/2024 10:09:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 01:15:54 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 09:02:00 PM
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2024 08:10:01 PM
- Novavax to Participate in BofA Securities 2024 Health Care Conference • PR Newswire (US) • 05/13/2024 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 06:39:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:07:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 12:05:26 PM
- Novavax Surges 57% Post $1.4 Billion Sanofi Deal; Apple Boosts Data Centers with AI and Internal Chips, and More News • IH Market News • 05/10/2024 12:02:56 PM
- Novavax Reports First Quarter 2024 Financial Results and Operational Highlights • PR Newswire (US) • 05/10/2024 06:15:00 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM